MiNK Therapeutics Hires Dr. Robert Kadlec as Board Member
MiNK Therapeutics, a pioneering clinical-stage biopharmaceutical company specializing in allogeneic off-the-shelf invariant natural killer T (iNKT) cell therapies, has made a significant addition to its leadership team with the appointment of Dr. Robert Kadlec to its Board of Directors. This strategic move is aimed at bolstering MiNK's efforts to address critical infectious diseases, including acute respiratory distress syndrome (ARDS) and other immune-related conditions.
Expertise Driving Innovation
Dr. Kadlec comes with an extensive background in biodefense and public health strategy, making his contribution to MiNK particularly valuable. His previous role as the U.S. Senate-confirmed Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) further underscores his capability to influence public health initiatives positively. During the challenging times of the COVID-19 pandemic, he played a pivotal role in developing the Operation Warp Speed vaccine initiative and led the overall pandemic response for HHS.
Commitment to Global Health
Jennifer Buell, PhD, the Chief Executive Officer and President of MiNK Therapeutics, expressed her enthusiasm about Dr. Kadlec's appointment. "We are thrilled to welcome Dr. Kadlec to our Board of Directors. His commitment to driving innovation in medical countermeasures, coupled with his profound public health knowledge, aligns perfectly with our mission. Together, we aim to utilize iNKT cells to tackle urgent global health challenges," she stated.
Dr. Kadlec's Background
Dr. Kadlec's impressive credentials include a bachelor’s degree from the United States Air Force Academy, a Doctor of Medicine, and a master's degree in tropical medicine and hygiene from the Uniformed Services University of the Health Sciences. Additionally, he holds a master's degree in national security studies from Georgetown University, complementing his robust portfolio in health and safety.
About MiNK Therapeutics
MiNK Therapeutics is on a mission to advance the discovery, development, and commercialization of innovative iNKT cell therapies that hold promise for treating various cancers and immune-mediated diseases. The company's focus on creating a scalable and reproducible manufacturing platform for off-the-shelf delivery reflects its commitment to addressing pressing medical needs. Headquartered in New York, NY, MiNK Therapeutics is dedicated to leveraging its expertise to enhance health outcomes.
Frequently Asked Questions
What is the role of Dr. Robert Kadlec at MiNK Therapeutics?
Dr. Kadlec has been appointed to the Board of Directors, bringing his extensive experience in biodefense and public health to the company.
What expertise does Dr. Kadlec bring to MiNK Therapeutics?
He has a strong background in public health, having led significant initiatives such as Operation Warp Speed during the COVID-19 pandemic.
What are the goals of MiNK Therapeutics?
MiNK aims to develop allogeneic iNKT cell therapies for treating cancer and immune-related diseases, focusing on scalable solutions.
How does Dr. Kadlec's background support MiNK Therapeutics?
His experience in public health strategy and disaster response will support MiNK in advancing its innovative therapies and navigating health challenges.
Where is MiNK Therapeutics headquartered?
MiNK Therapeutics is headquartered in New York, NY, and is committed to developing groundbreaking health solutions.
